# Cytek Biosciences, Inc.: financial statements, quarterly

CTKB · Nasdaq · CIK 1831915 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ctkb.md) · [Financials](/companies/ctkb/financials.md) · [Filings](/companies/ctkb/filings.md) · [Insiders](/companies/ctkb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ctkb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [48.0](/filings/0001628280-24-045834.md) | [58.2 d](/filings/0001628280-26-012352.md) | [44.9](/filings/0001628280-25-023927.md) | [46.6](/filings/0001628280-25-038422.md) | [51.5](/filings/0001628280-25-049697.md) | [57.5 d](/filings/0001628280-26-012352.md) | [41.5](/filings/0001628280-26-032293.md) | [45.6](/filings/0001628280-26-053496.md) | [52.3](/filings/0001628280-25-049697.md) | [62.1 d](/filings/0001628280-26-012352.md) | [44.1](/filings/0001628280-26-032293.md) | [48.1](/filings/0001628280-26-053496.md) |
| Cost of revenue | $m | [20.8](/filings/0001628280-24-045834.md) | [25.2 d](/filings/0001628280-26-012352.md) | [21.8](/filings/0001628280-25-023927.md) | [21.2](/filings/0001628280-25-038422.md) | [22.5](/filings/0001628280-25-049697.md) | [23.8 d](/filings/0001628280-26-012352.md) | [21.3](/filings/0001628280-26-032293.md) | [21.7](/filings/0001628280-26-053496.md) | [24.7](/filings/0001628280-25-049697.md) | [29.3 d](/filings/0001628280-26-012352.md) | [22.9](/filings/0001628280-26-032293.md) | [19.8](/filings/0001628280-26-053496.md) |
| Gross profit | $m | [27.2](/filings/0001628280-24-045834.md) | [33.0 d](/filings/0001628280-26-012352.md) | [23.0](/filings/0001628280-25-023927.md) | [25.4](/filings/0001628280-25-038422.md) | [29.0](/filings/0001628280-25-049697.md) | [33.7 d](/filings/0001628280-26-012352.md) | [20.2](/filings/0001628280-26-032293.md) | [23.9](/filings/0001628280-26-053496.md) | [27.6](/filings/0001628280-25-049697.md) | [32.9 d](/filings/0001628280-26-012352.md) | [21.3](/filings/0001628280-26-032293.md) | [28.3](/filings/0001628280-26-053496.md) |
| Research and development | $m | [11.2](/filings/0001628280-24-045834.md) | [10.9 d](/filings/0001628280-26-012352.md) | [9.8](/filings/0001628280-25-023927.md) | [10.0](/filings/0001628280-25-038422.md) | [9.9](/filings/0001628280-25-049697.md) | [9.7 d](/filings/0001628280-26-012352.md) | [9.7](/filings/0001628280-26-032293.md) | [8.8](/filings/0001628280-26-053496.md) | [9.0](/filings/0001628280-25-049697.md) | [9.0 d](/filings/0001628280-26-012352.md) | [9.6](/filings/0001628280-26-032293.md) | [9.7](/filings/0001628280-26-053496.md) |
| Operating income | $m | [(6.4)](/filings/0001628280-24-045834.md) | [(0.1) d](/filings/0001628280-26-012352.md) | [(10.7)](/filings/0001628280-25-023927.md) | [(8.5)](/filings/0001628280-25-038422.md) | [(4.2)](/filings/0001628280-25-049697.md) | [3.0 d](/filings/0001628280-26-012352.md) | [(15.0)](/filings/0001628280-26-032293.md) | [(10.6)](/filings/0001628280-26-053496.md) | [(9.2)](/filings/0001628280-25-049697.md) | [(5.6) d](/filings/0001628280-26-012352.md) | [(18.5)](/filings/0001628280-26-032293.md) | [(11.4)](/filings/0001628280-26-053496.md) |
| Interest expense | $m | [0.6](/filings/0001628280-23-038974.md) | [0.4 d](/filings/0001628280-24-010933.md) | [0.4](/filings/0001628280-24-021723.md) | [0.1](/filings/0001628280-25-038422.md) | [0.1](/filings/0001628280-25-049697.md) | [(5.9) d](/filings/0001628280-26-012352.md) | [0.3](/filings/0001628280-26-032293.md) | [0.4](/filings/0001628280-26-053496.md) | [0.5](/filings/0001628280-25-049697.md) | [(0.7) d](/filings/0001628280-26-012352.md) | [0.3](/filings/0001628280-26-032293.md) | [0.3](/filings/0001628280-26-053496.md) |
| Income tax | $m | [2.3](/filings/0001628280-24-045834.md) | [(1.4) d](/filings/0001628280-26-012352.md) | [(2.8)](/filings/0001628280-25-023927.md) | [3.2](/filings/0001628280-25-038422.md) | [(0.8)](/filings/0001628280-25-049697.md) | [0.7 d](/filings/0001628280-26-012352.md) | [0.1](/filings/0001628280-26-032293.md) | [(1.2)](/filings/0001628280-26-053496.md) | [(2.3)](/filings/0001628280-25-049697.md) | [40.0 d](/filings/0001628280-26-012352.md) | [1.5](/filings/0001628280-26-032293.md) | [0.5](/filings/0001628280-26-053496.md) |
| Net income | $m | [(6.5)](/filings/0001628280-24-045834.md) | [5.5 d](/filings/0001628280-26-012352.md) | [(6.2)](/filings/0001628280-25-023927.md) | [(10.4)](/filings/0001628280-25-049697.md) | [0.9](/filings/0001628280-25-049697.md) | [9.6 d](/filings/0001628280-26-012352.md) | [(11.4)](/filings/0001628280-26-053496.md) | [(5.6)](/filings/0001628280-26-053496.md) | [(5.5)](/filings/0001628280-25-049697.md) | [(44.1) d](/filings/0001628280-26-012352.md) | [(18.9)](/filings/0001628280-26-053496.md) | [(12.2)](/filings/0001628280-26-053496.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss, us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: not reported

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [164](/filings/0001628280-23-038974.md) | [167](/filings/0001628280-25-008780.md) | [169](/filings/0001628280-24-021723.md) | [178](/filings/0001628280-24-035264.md) | [162](/filings/0001628280-24-045834.md) | [98.7](/filings/0001628280-26-012352.md) | [95.3](/filings/0001628280-25-023927.md) | [75.5](/filings/0001628280-25-038422.md) | [93.3](/filings/0001628280-25-049697.md) | [90.9](/filings/0001628280-26-053496.md) | [65.7](/filings/0001628280-26-032293.md) | [73.8](/filings/0001628280-26-053496.md) |
| Current assets | $m | [422](/filings/0001628280-23-038974.md) | [392](/filings/0001628280-25-008780.md) | [389](/filings/0001628280-24-021723.md) | [384](/filings/0001628280-24-035264.md) | [390](/filings/0001628280-24-045834.md) | [396](/filings/0001628280-26-012352.md) | [381](/filings/0001628280-25-023927.md) | [383](/filings/0001628280-25-038422.md) | [388](/filings/0001628280-25-049697.md) | [392](/filings/0001628280-26-053496.md) | [379](/filings/0001628280-26-032293.md) | [378](/filings/0001628280-26-053496.md) |
| Total assets | $m | [519](/filings/0001628280-23-038974.md) | [494](/filings/0001628280-25-008780.md) | [492](/filings/0001628280-24-021723.md) | [484](/filings/0001628280-24-035264.md) | [491](/filings/0001628280-24-045834.md) | [500](/filings/0001628280-26-012352.md) | [483](/filings/0001628280-25-023927.md) | [493](/filings/0001628280-25-038422.md) | [495](/filings/0001628280-25-049697.md) | [462](/filings/0001628280-26-053496.md) | [449](/filings/0001628280-26-032293.md) | [447](/filings/0001628280-26-053496.md) |
| Current liabilities | $m | [58.7](/filings/0001628280-23-038974.md) | [56.2](/filings/0001628280-25-008780.md) | [55.6](/filings/0001628280-24-021723.md) | [52.4](/filings/0001628280-24-035264.md) | [62.8](/filings/0001628280-24-045834.md) | [67.7](/filings/0001628280-26-012352.md) | [67.7](/filings/0001628280-25-023927.md) | [73.3](/filings/0001628280-25-038422.md) | [75.2](/filings/0001628280-25-049697.md) | [77.8](/filings/0001628280-26-053496.md) | [80.9](/filings/0001628280-26-032293.md) | [84.3](/filings/0001628280-26-053496.md) |
| Total liabilities | $m | [104](/filings/0001628280-23-038974.md) | [101](/filings/0001628280-25-008780.md) | [99.5](/filings/0001628280-24-021723.md) | [94.6](/filings/0001628280-24-035264.md) | [106](/filings/0001628280-24-045834.md) | [104](/filings/0001628280-26-012352.md) | [103](/filings/0001628280-25-023927.md) | [116](/filings/0001628280-25-038422.md) | [116](/filings/0001628280-25-049697.md) | [120](/filings/0001628280-26-053496.md) | [121](/filings/0001628280-26-032293.md) | [125](/filings/0001628280-26-053496.md) |
| Shareholders' equity | $m | [416](/filings/0001628280-24-045834.md) | [393](/filings/0001628280-25-049697.md) | [393](/filings/0001628280-25-049697.md) | [389](/filings/0001628280-25-049697.md) | [385](/filings/0001628280-25-049697.md) | [396](/filings/0001628280-26-053496.md) | [380](/filings/0001628280-26-053496.md) | [378](/filings/0001628280-26-053496.md) | [379](/filings/0001628280-25-049697.md) | [342](/filings/0001628280-26-053496.md) | [328](/filings/0001628280-26-053496.md) | [322](/filings/0001628280-26-053496.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.2) d](/filings/0001628280-24-045834.md) | [9.5 d](/filings/0001628280-26-012352.md) | [4.0](/filings/0001628280-25-023927.md) | [6.2 d](/filings/0001628280-25-038422.md) | [13.2 d](/filings/0001628280-25-049697.md) | [2.0 d](/filings/0001628280-26-012352.md) | [(0.1)](/filings/0001628280-26-032293.md) | [0.1 d](/filings/0001628280-26-053496.md) | [(3.9) d](/filings/0001628280-25-049697.md) | [(0.8) d](/filings/0001628280-26-012352.md) | [(2.7)](/filings/0001628280-26-032293.md) | [1.4 d](/filings/0001628280-26-053496.md) |
| Capital expenditure | $m | [1.3 d](/filings/0001628280-24-045834.md) | [1.5 d](/filings/0001628280-26-012352.md) | [0.6](/filings/0001628280-25-023927.md) | [1.1 d](/filings/0001628280-25-038422.md) | [1.0 d](/filings/0001628280-25-049697.md) | [0.9 d](/filings/0001628280-26-012352.md) | [0.8](/filings/0001628280-26-032293.md) | [1.6 d](/filings/0001628280-26-053496.md) | [0.7 d](/filings/0001628280-25-049697.md) | [1.0 d](/filings/0001628280-26-012352.md) | [2.2](/filings/0001628280-26-032293.md) | [2.2 d](/filings/0001628280-26-053496.md) |
| Share repurchases | $m | not reported | [34.6](/filings/0001628280-26-012352.md) | [0.0](/filings/0001628280-25-023927.md) | [2.7](/filings/0001628280-24-035264.md) | [11.9](/filings/0001628280-24-045834.md) | [7.0](/filings/0001628280-26-012352.md) | [10.6](/filings/0001628280-26-032293.md) | [4.5 d](/filings/0001628280-26-053496.md) | [(0.0) d](/filings/0001628280-25-049697.md) | [(0.0) d](/filings/0001628280-26-012352.md) | [0.0](/filings/0001628280-26-032293.md) | [0.0 d](/filings/0001628280-26-053496.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [139](/filings/0001628280-23-038974.md) | [135](/filings/0001628280-24-021723.md) | [136](/filings/0001628280-24-035264.md) | [136](/filings/0001628280-24-045834.md) | [131](/filings/0001628280-25-023927.md) | [131](/filings/0001628280-25-038422.md) | [133](/filings/0001628280-25-049697.md) | [128](/filings/0001628280-26-032293.md) | [127](/filings/0001628280-26-053496.md) | [128](/filings/0001628280-25-049697.md) | [129](/filings/0001628280-26-032293.md) | [129](/filings/0001628280-26-053496.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 129,983,253 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053496.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.